Zenda Technologies
Roswell
About Zenda Technologies
Zenda has a patent pending technology that for the first time makes it practical for your primary care physician to include a 7-10 minute scan for the earliest cognitive change signs of dementia including Alzheimer’s Disease - starting at age 50. All too often cognitve problems such as Alzheimer’s disease are diagnosed late in the disease cycle. Zenda’s DETECT test enables physicians to diagnose early when drug therapies and even life style changes are the most effective. Zenda has completed several clinical studies; including the latest with 400 patients and the results are excellent. These studies show that the DETECT test on the IMTech immersive neuropsychological testing platform is as accurate in 10 minutes as the gold standard 90 minute test.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.0M
- Funding stage: Seed
- Last round: Seed (Jan 2008)
- Website: zendatech.com
- Phone: 404-492-9226
Industries & Categories
Biotechnology, Health Care, Medical Device, Primary and Urgent Care
Social Profiles
Canonical: https://fsome.com/organization/zenda-technologies-1258248 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.